title: VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration.
abstract: OBJECTIVE
  To investigate the association between VEGF gene polymorphism and response to ranibizumab in neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  A total of 92 patients were genotyped for the VEGF rs1413711 single nucleotide polymorphism. Patients with neovascular AMD initially received 3 monthly ranibizumab intravitreal injections and were retreated as needed. Visual acuity (VA) and central retinal thickness (CRT) were measured before and 1, 3, 6 and 12 months after treatment.
  
  
  RESULTS
  For patients with TT and CT genotypes, paired comparisons of mean VA showed improvement when the data obtained at all visits were compared with baseline values, in contrast to patients with the CC genotype. CRT statistically improved at all visits for all genotypes.
  
  
  CONCLUSIONS
  Patients with the CC genotype showed poorer long-term functional and anatomical response to anti-VEGF therapy.
authors.affiliation: Department of Ophthalmology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
authors.forename: Carlos Eduardo dos Reis
authors.initials: CE
authors.lastname: Veloso
authors.forename: Luciana Negrão Frota
authors.initials: LN
authors.lastname: de Almeida
authors.forename: Franco Maria
authors.initials: FM
authors.lastname: Recchia
authors.forename: David
authors.initials: D
authors.lastname: Pelayes
authors.forename: Márcio Bittar
authors.initials: MB
authors.lastname: Nehemy
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D005838:Genotype; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D000069579:Ranibizumab; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab